Company News »

INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis

Business Wire
Share on StockTwits
Published on

Levi & Korsinsky is investigating the Board of Directors of Durata Therapeutics Inc. (“Durata” or “the Company”) (NASDAQ:DRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Actavis (NYSE:ACT) .

Click here to learn more about the investigation:

Under the terms of the transaction, Durata shareholders will receive $23.00 in cash for each share of Durata stock they own, as well as contingent value rights entitling the holder to receive additional cash payments of up to $5.00 per share upon certain achieved milestones. The investigation concerns whether the Board of Durata breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Actavis is underpaying for Durata shares.

If you own Durata common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Share on StockTwits